Terms: = Kidney tumors AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809 AND Clinical Outcome
20 results:
1. Low-grade oncocytic renal tumor (LOT): mutations in mtor pathway genes and low expression of FOXI1.
Morini A; Drossart T; Timsit MO; Sibony M; Vasiliu V; Gimenez-Roqueplo AP; Favier J; Badoual C; Mejean A; Burnichon N; Verkarre V
Mod Pathol; 2022 Mar; 35(3):352-360. PubMed ID: 34531523
[TBL] [Abstract] [Full Text] [Related]
2. Landscape of immune cell infiltration in clear cell renal cell carcinoma to aid immunotherapy.
Bai D; Feng H; Yang J; Yin A; Qian A; Sugiyama H
Cancer Sci; 2021 Jun; 112(6):2126-2139. PubMed ID: 33735492
[TBL] [Abstract] [Full Text] [Related]
3. Activity of lenvatinib plus everolimus combination in a heavily pretreated patient with papillary renal cell carcinoma: a case report.
Zielli T; Gnetti L; Buti S
Tumori; 2020 Dec; 106(6):NP79-NP83. PubMed ID: 32458743
[TBL] [Abstract] [Full Text] [Related]
4. Metronomic cyclophosphamide attenuates mtor-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus.
Werter IM; Huijts CM; Lougheed SM; Hamberg P; Polee MB; Tascilar M; Los M; Haanen JBAG; Helgason HH; Verheul HM; de Gruijl TD; van der Vliet HJ;
Cancer Immunol Immunother; 2019 May; 68(5):787-798. PubMed ID: 30756132
[TBL] [Abstract] [Full Text] [Related]
5. mtor and mtor phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.
Rausch S; Schollenberger D; Hennenlotter J; Stühler V; Kruck S; Stenzl A; Bedke J
J Cancer Res Clin Oncol; 2019 Jan; 145(1):153-163. PubMed ID: 30368665
[TBL] [Abstract] [Full Text] [Related]
6. A tightly controlled Src-YAP signaling axis determines therapeutic response to dasatinib in renal cell carcinoma.
Sun J; Wang X; Tang B; Liu H; Zhang M; Wang Y; Ping F; Ding J; Shen A; Geng M
Theranostics; 2018; 8(12):3256-3267. PubMed ID: 29930727
[TBL] [Abstract] [Full Text] [Related]
7. clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer.
Iacovelli R; Cossu Rocca M; Galli L; De Giorgi U; Sabbatini R; Santoni M; Mosca A; Fornarini G; Massari F; Masini C; Bersanelli M; Biasco E; Lolli C; Guida A; Berardi R; Terrone C; Pastorino A; Ardizzoni A; Pinto C; Buti S; Nolè F; Tortora G
Urol Oncol; 2017 Sep; 35(9):541.e7-541.e13. PubMed ID: 28572027
[TBL] [Abstract] [Full Text] [Related]
8. clinical presentations and molecular studies of invasive renal epithelioid angiomyolipoma.
Chuang CK; Lin HCA; Tasi HY; Lee KH; Kao Y; Chuang FL; Chang YH; Lin PH; Liu CY; Pang ST
Int Urol Nephrol; 2017 Sep; 49(9):1527-1536. PubMed ID: 28547571
[TBL] [Abstract] [Full Text] [Related]
9. Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets.
Chen YB; Xu J; Skanderup AJ; Dong Y; Brannon AR; Wang L; Won HH; Wang PI; Nanjangud GJ; Jungbluth AA; Li W; Ojeda V; Hakimi AA; Voss MH; Schultz N; Motzer RJ; Russo P; Cheng EH; Giancotti FG; Lee W; Berger MF; Tickoo SK; Reuter VE; Hsieh JJ
Nat Commun; 2016 Oct; 7():13131. PubMed ID: 27713405
[TBL] [Abstract] [Full Text] [Related]
10. Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma.
Incorvaia L; Bronte G; Bazan V; Badalamenti G; Rizzo S; Pantuso G; Natoli C; Russo A
Oncotarget; 2016 Apr; 7(16):21259-71. PubMed ID: 26872372
[TBL] [Abstract] [Full Text] [Related]
11. Percutaneous cryoablation for tuberous sclerosis-associated renal angiomyolipoma with neoadjuvant mtor inhibition.
Krummel T; Garnon J; Lang H; Gangi A; Hannedouche T
BMC Urol; 2014 Sep; 14():77. PubMed ID: 25258166
[TBL] [Abstract] [Full Text] [Related]
12. Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
Bellmunt J; Pons F; Foreshew A; Fay AP; Powles T; Porta C; Bracarda S; Lampron ME; Cerbone L; Sternberg CN; Hutson TE; Choueiri TK
Clin Genitourin Cancer; 2014 Aug; 12(4):262-9. PubMed ID: 24795159
[TBL] [Abstract] [Full Text] [Related]
13. Targeting both IGF-1R and mtor synergistically inhibits growth of renal cell carcinoma in vitro.
Cardillo TM; Trisal P; Arrojo R; Goldenberg DM; Chang CH
BMC Cancer; 2013 Apr; 13():170. PubMed ID: 23548153
[TBL] [Abstract] [Full Text] [Related]
14. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.
Tran HT; Liu Y; Zurita AJ; Lin Y; Baker-Neblett KL; Martin AM; Figlin RA; Hutson TE; Sternberg CN; Amado RG; Pandite LN; Heymach JV
Lancet Oncol; 2012 Aug; 13(8):827-37. PubMed ID: 22759480
[TBL] [Abstract] [Full Text] [Related]
15. Pneumonitis associated with mtor inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome.
Dabydeen DA; Jagannathan JP; Ramaiya N; Krajewski K; Schutz FA; Cho DC; Pedrosa I; Choueiri TK
Eur J Cancer; 2012 Jul; 48(10):1519-24. PubMed ID: 22483544
[TBL] [Abstract] [Full Text] [Related]
16. Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma.
Busch J; Seidel C; Weikert S; Wolff I; Kempkensteffen C; Weinkauf L; Hinz S; Magheli A; Miller K; Grünwald V
BMC Cancer; 2011 Jul; 11():295. PubMed ID: 21756335
[TBL] [Abstract] [Full Text] [Related]
17. Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action.
Larkin J; Swanton C; Pickering L
Expert Rev Anticancer Ther; 2011 Apr; 11(4):639-49. PubMed ID: 21504330
[TBL] [Abstract] [Full Text] [Related]
18. clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy.
Vickers MM; Choueiri TK; Rogers M; Percy A; Finch D; Zama I; Cheng T; North S; Knox JJ; Kollmannsberger C; McDermott DF; Rini BI; Heng DY
Urology; 2010 Aug; 76(2):430-4. PubMed ID: 20223508
[TBL] [Abstract] [Full Text] [Related]
19. Targeted anti-cancer therapies for renal cancer.
Amato RJ; Jac J
Drugs; 2006; 66(17):2161-71. PubMed ID: 17137401
[TBL] [Abstract] [Full Text] [Related]
20. Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma.
Burczynski ME; Twine NC; Dukart G; Marshall B; Hidalgo M; Stadler WM; Logan T; Dutcher J; Hudes G; Trepicchio WL; Strahs A; Immermann F; Slonim DK; Dorner AJ
Clin Cancer Res; 2005 Feb; 11(3):1181-9. PubMed ID: 15709187
[TBL] [Abstract] [Full Text] [Related]